- Home
- IONS vs GLPI Comparison
IONS vs GLPI Comparison
Compare IONS & GLPI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IONS | GLPI |
|---|---|---|
| Founded | 1989 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.1B | 12.6B |
| IPO Year | 1996 | 2013 |
Fundamental Metrics
Financial Performance| Metric | IONS | GLPI |
|---|---|---|
| Price | $42.38 | $38.35 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 24 | 24 |
| Target Price | ★ $83.64 | $51.65 |
| AVG Volume (30 Days) | ★ 3.9M | 2.9M |
| Earning Date | 10-28-2026 | 10-29-2026 |
| Dividend Yield | N/A | ★ 8.52% |
| EPS Growth | ★ 21.71 | 2.79 |
| EPS | N/A | ★ 1.62 |
| Revenue | N/A | ★ $1,594,752,000.00 |
| Revenue This Year | N/A | $8.48 |
| Revenue Next Year | $48.21 | $5.90 |
| P/E Ratio | ★ N/A | $23.74 |
| Revenue Growth | N/A | ★ 4.13 |
| 52 Week Low | $42.63 | $37.33 |
| 52 Week High | $86.74 | $49.95 |
Technical Indicators
Market Signals| Indicator | IONS | GLPI |
|---|---|---|
| Relative Strength Index (RSI) | 33.59 | 37.05 |
| Support Level | N/A | $37.33 |
| Resistance Level | $46.95 | $46.21 |
| Average True Range (ATR) | 1.55 | 0.64 |
| MACD | 0.38 | 0.16 |
| Stochastic Oscillator | 7.89 | 52.27 |
Price Performance
Historical ComparisonAbout IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
About GLPI Gaming and Leisure Properties Inc.
Gaming and Leisure Properties Inc, or GLP, is a self-administered and self-managed Pennsylvania real estate investment trust (REIT). It is engaged in acquiring, financing, and owning real estate property to be leased to gaming operators in triple-net lease arrangements. The company also extends loans that produce fixed or variable returns, which may convert into leased rent upon project completion or stabilization. Its portfolio consists of gaming and related facilities and amenities such as Ameristar Black Hawk, Bally's Casino, Argosy Casino Alton, Bally's Chicago, Hollywood Casino Aurora, and others located across different states in the United States.